Physician profile
Michael D Cannaday
NPI 1851472781
$5,063.65
in general payments reported to CMS, 2019-2025
29 companies · $612 in 2025
The $612 reported for 2025 was more than what 77% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $676 · 2020: $804 · 2021: $712 · 2022: $666 · 2023: $797 · 2024: $798 · 2025: $612.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,207.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,207.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,307.97 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $713.85 | 2020-2025 | Jardiance, Tradjenta, Synjardy |
| Lilly USA, LLC | $489.27 | 2019-2025 | Mounjaro, Zepbound |
| Astrazeneca Pharmaceuticals Lp | $369.34 | 2019-2024 | Breztri, Airsupra |
| Astellas Pharma US INC | $361.25 | 2019-2025 | Veozah, Myrbetriq |
| Pfizer INC. | $334.50 | 2019-2025 | |
| Exact Sciences Corporation | $212.36 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Novartis Pharmaceuticals Corporation | $173.83 | 2019-2023 | |
| Amgen INC. | $170.19 | 2019-2025 | Otezla, Repatha |
| Vanda Pharmaceuticals INC. | $127.75 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $99.19 | 2019-2022 | |
| Abbott Laboratories | $83.49 | 2021-2022 | |
| Allergan, INC. | $67.29 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $59.99 | 2022 | |
| Hikma Pharmaceuticals USA | $52.13 | 2019-2021 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $51.39 | 2022-2023 | Quviviq |
| Seqirus USA INC | $51.28 | 2024-2025 | Fluad, Flucelvax |
| Arbor Pharmaceuticals, INC. | $50.78 | 2020-2021 | |
| Kowa Pharmaceuticals America, INC. | $44.17 | 2021-2022 | |
| Sanofi Pasteur INC. | $37.83 | 2019-2023 | |
| Horizon Therapeutics Plc | $34.23 | 2020-2022 | |
| Janssen Pharmaceuticals, INC | $31.75 | 2019 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $27.78 | 2022 | |
| Dexcom, INC. | $22.14 | 2024 | Dexcom G6 Transmitter |
| Biogen, INC. | $21.60 | 2021 | |
| Amarin Pharma, INC. | $21.32 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $17.66 | 2025 | Eliquis |
| Abbvie INC. | $16.32 | 2021 | |
| Eyevance Pharmaceuticals LLC | $13.00 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Cannaday listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.